EMA Authorised: Toviaz (fesoterodine fumarate) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Toviaz (fesoterodine fumarate) for the treatment of overactive bladder, with Pfizer Europe MA EEIG as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Toviaz (fesoterodine fumarate)

Snippet

Status: Authorised. Therapeutic area: Urinary Bladder, Overactive. MAH: Pfizer Europe MA EEIG. Decision date: 03/03/2025